Blue Trust Inc. Sells 892 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Blue Belief Inc. reduce its stake in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) by 49.7% through the third quarter, based on its most up-to-date 13F submitting with the Securities and Alternate Fee. The agency owned 901 shares of the medical analysis firm’s inventory after promoting 892 shares through the quarter. Blue Belief Inc.’s holdings in Laboratory Co. of America had been price $183,000 as of its most up-to-date SEC submitting.

Different institutional traders additionally lately modified their holdings of the corporate. Financial institution of New York Mellon Corp boosted its stake in Laboratory Co. of America by 135.0% through the 2nd quarter. Financial institution of New York Mellon Corp now owns 1,609,826 shares of the medical analysis firm’s inventory valued at $327,616,000 after buying a further 924,881 shares over the past quarter. Diamond Hill Capital Administration Inc. raised its stake in shares of Laboratory Co. of America by 25.4% through the 2nd quarter. Diamond Hill Capital Administration Inc. now owns 1,949,640 shares of the medical analysis firm’s inventory valued at $396,771,000 after buying a further 395,197 shares through the interval. Choose Fairness Group L.P. bought a brand new place in Laboratory Co. of America through the second quarter valued at roughly $73,928,000. Magnetar Monetary LLC bought a brand new place in Laboratory Co. of America through the first quarter price about $45,567,000. Lastly, Cooke & Bieler LP lifted its place in Laboratory Co. of America by 26.8% through the second quarter. Cooke & Bieler LP now owns 928,250 shares of the medical analysis firm’s inventory valued at $188,908,000 after buying a further 196,119 shares over the past quarter. 95.94% of the inventory is owned by institutional traders.

Laboratory Co. of America Inventory Down 0.6 %

LH opened at $228.63 on Friday. The corporate has a debt-to-equity ratio of 0.39, a fast ratio of 0.77 and a present ratio of 0.88. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week excessive of $239.50. The agency’s fifty day transferring common is $222.60 and its 200 day transferring common is $212.39. The inventory has a market cap of $19.20 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 1.70 and a beta of 1.05.

Laboratory Co. of America (NYSE:LH – Get Free Report) final issued its earnings outcomes on Thursday, October twenty fourth. The medical analysis firm reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.02. Laboratory Co. of America had a return on fairness of 15.39% and a internet margin of three.60%. The agency had income of $3.28 billion for the quarter, in comparison with analysts’ expectations of $3.26 billion. Throughout the identical interval within the earlier 12 months, the agency posted $3.38 earnings per share. The enterprise’s income was up 7.4% in comparison with the identical quarter final 12 months. On common, sell-side analysts forecast that Laboratory Co. of America Holdings will publish 14.55 earnings per share for the present fiscal 12 months.

Laboratory Co. of America Pronounces Dividend

The enterprise additionally lately introduced a quarterly dividend, which will likely be paid on Friday, December thirteenth. Stockholders of file on Tuesday, November twenty sixth will likely be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Tuesday, November twenty sixth. Laboratory Co. of America’s dividend payout ratio is at the moment 54.55%.

Insider Exercise

In different Laboratory Co. of America information, EVP Lance Berberian offered 12,093 shares of the corporate’s inventory in a transaction on Monday, August fifth. The inventory was offered at a mean worth of $229.10, for a complete worth of $2,770,506.30. Following the transaction, the manager vp now owns 15,921 shares of the corporate’s inventory, valued at $3,647,501.10. This represents a 0.00 % lower of their place. The sale was disclosed in a authorized submitting with the SEC, which is offered via this hyperlink. In different Laboratory Co. of America information, EVP Lance Berberian offered 12,093 shares of the corporate’s inventory in a transaction on Monday, August fifth. The inventory was offered at a mean worth of $229.10, for a complete worth of $2,770,506.30. Following the completion of the sale, the manager vp now straight owns 15,921 shares within the firm, valued at roughly $3,647,501.10. This represents a 0.00 % lower of their place. The sale was disclosed in a submitting with the Securities & Alternate Fee, which may be accessed via this hyperlink. Additionally, Director Kerrii B. Anderson offered 586 shares of the enterprise’s inventory in a transaction dated Thursday, August eighth. The shares had been offered at a mean worth of $225.00, for a complete transaction of $131,850.00. Following the completion of the sale, the director now owns 14,722 shares of the corporate’s inventory, valued at roughly $3,312,450. This represents a 0.00 % lower of their place. The disclosure for this sale may be discovered right here. Over the past quarter, insiders have offered 30,679 shares of firm inventory valued at $6,946,306. 0.85% of the inventory is at the moment owned by firm insiders.

Wall Road Analysts Forecast Development

A number of analysis analysts have commented on the inventory. Barclays lifted their worth goal on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the inventory an “equal weight” score in a analysis word on Friday. StockNews.com downgraded shares of Laboratory Co. of America from a “purchase” score to a “maintain” score in a analysis report on Friday. Evercore ISI decreased their goal worth on Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” score for the corporate in a analysis report on Tuesday, September twenty fourth. UBS Group boosted their worth goal on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the inventory a “purchase” score in a analysis word on Friday, August 2nd. Lastly, Robert W. Baird lifted their goal worth on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the inventory an “outperform” score in a report on Friday. 5 analysis analysts have rated the inventory with a maintain score and ten have given a purchase score to the inventory. Primarily based on knowledge from MarketBeat.com, Laboratory Co. of America presently has a mean score of “Average Purchase” and a mean goal worth of $253.54.

Get Our Newest Evaluation on LH

Laboratory Co. of America Firm Profile

(Free Report)

Labcorp Holdings Inc supplies laboratory providers. It operates via two segments, Diagnostics Laboratories and Biopharma Laboratory Providers. The corporate gives varied exams, similar to blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted illnesses, hepatitis C, microbiology cultures and procedures, and alcohol and different substance-abuse exams.

Really useful Tales

Obtain Information & Rankings for Laboratory Co. of America Each day – Enter your electronic mail tackle beneath to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Laboratory Co. of America and associated firms with MarketBeat.com’s FREE day by day electronic mail e-newsletter.